Advanced or Recurrent Solid Tumors

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
1 program
1
E7090Phase 21 trial
Active Trials
NCT04962867Recruiting75Est. Mar 2028
BioGene Therapeutics
1 program
1
Injections Subcutaneously TalazoparibPhase 11 trial
Active Trials
NCT03426254WithdrawnEst. Jan 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
EisaiE7090
BioGene TherapeuticsInjections Subcutaneously Talazoparib

Clinical Trials (2)

Total enrollment: 75 patients across 2 trials

NCCH2006/MK010 Trial (FORTUNE Trial)

Start: Jun 2021Est. completion: Mar 202875 patients
Phase 2Recruiting
NCT03426254BioGene TherapeuticsInjections Subcutaneously Talazoparib

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Start: Nov 2022Est. completion: Jan 2024
Phase 1Withdrawn

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 75 patients
2 companies competing in this space